SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Astrazeneca Pharma I - Quaterly Results

08 Feb 2024 Evaluate
A fair growth of 22.41% in the revenue at Rs. 3057.89 millions was reported in the December 2023 quarter as compared to Rs. 2498.08 millions during year-ago period.Net profit of the cmpany stood at Rs. 158.00 millions for the quarter ended December 2023 a decline of -46.09% from Rs. 293.06 millions  in the same quarter last year.Operating Profit reported a sharp decline to 247.16 millions from 437.86 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 3057.89 2498.08 22.41 9123.28 7182.67 27.02 10029.71 8056.00 24.50
Other Income 96.60 71.96 34.24 261.37 181.04 44.37 261.02 147.58 76.87
PBIDT 247.16 437.86 -43.55 1611.97 1233.83 30.65 1914.27 1009.33 89.66
Interest 6.13 1.96 212.76 12.67 5.44 132.90 8.33 9.47 -12.04
PBDT 241.03 435.90 -44.71 1763.56 1228.39 43.57 1503.65 999.86 50.39
Depreciation 37.05 41.32 -10.33 111.77 120.11 -6.94 162.60 169.49 -4.07
PBT 203.98 394.58 -48.30 1651.79 1108.28 49.04 1341.05 830.37 61.50
TAX 45.98 101.52 -54.71 431.50 288.02 49.82 348.12 214.43 62.35
Deferred Tax -0.55 3.06 -117.97 -2.64 -11.18 -76.39 -34.90 -11.86 194.27
PAT 158.00 293.06 -46.09 1220.29 820.26 48.77 992.93 615.94 61.21
Equity 50.00 50.00 0.00 50.00 50.00 0.00 50.00 50.00 0.00
PBIDTM(%) 8.08 17.53 -53.89 17.67 17.18 2.86 19.09 12.53 52.34

Astrazeneca Pharma I Share Price

8508.80 -16.30 (-0.19%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×